Clinical trial NCT03369236: A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
Official title: A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G), With an Open-label Extension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: C3 Glomerulopathy
C3 Glomerulonephritis
Dense Deposit Disease
Keywords: factor D
fD
Alternative pathway
Complement mediated disease
Membranoproliferative Glomerulonephritis
Primary MPGN
MPGN
Mesangiocapillary Glomerulonephritis
Idiopathic MPGN
DDD
C3GN
Lead sponsor: Alexion Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2017-12-11
Enrollment: 13
Sex: ALL
Minimum age (years): 17
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this proof-of-concept clinical study was to evaluate the efficacy and safety of the study drug, ACH-0144471 (also known as danicopan and ALXN2040), in participants with C3G who also had significant proteinuria attributable to C3G.


Eligibility criteria: Key Inclusion Criteria:

* Had biopsy-confirmed primary C3G
* Had clinical evidence of ongoing disease based on significant proteinuria, attributable to C3G disease in the opinion of the Principal Investigator (PI), and present prior to study entry and confirmed during Screening
* Was willing to comply with vaccination requirements.

Key Exclusion Criteria:

* Had a history or presence of any clinically relevant co-morbidities that would make the participant inappropriate for the study
* Had ever received danicopan
* Had more than 50% fibrosis or more than 50% of glomeruli with cellular crescents on the pre-treatment renal biopsy
* Had an estimated glomerular filtration rate \<30 milliliters/minute/1.73 meters squared at the time of screening or at any time over the preceding 4 weeks
* Was a renal transplant recipient or receiving renal replacement therapy
* Had a history of a major organ transplant or hematopoietic stem cell/marrow transplant
* Had evidence of monoclonal gammopathy of unclear significance, infections, malignancy, autoimmune diseases, or other conditions to which C3G is secondary
* Had other renal diseases that would interfere with interpretation of the study
* Had been diagnosed with or showed evidence of hepatobiliary cholestasis
* Females who were pregnant, nursing, or planning to become pregnant during the study or within 90 days of study drug administration
* Had a history of febrile illness, a body temperature \>38°Celsius, or other evidence of a clinically significant active infection, within 14 days prior to study drug administration
* Had evidence of human immunodeficiency virus, hepatitis B infection, or active hepatitis C infection at Screening
* Had laboratory abnormalities at screening that, in the opinion of the PI, would make the participant inappropriate for the study

Primary outcomes:
measure: Change From Baseline In Composite Biopsy Score At Week 28
timeFrame: Baseline, Week 28
measure: Participants With Reduction In Proteinuria At Week 28
timeFrame: Week 28
Secondary outcomes:
measure: Change From Baseline In Proteinuria At Week 28
timeFrame: Baseline, Week 28
measure: Percent Change From Baseline In Proteinuria At Week 28
timeFrame: Baseline, Week 28
measure: Slope Of Estimated Glomerular Filtration Rate (eGFR) From Baseline To 6 Months
timeFrame: 6 months
measure: Slope Of Estimated Glomerular Filtration Rate (eGFR) After Open-label Danicopan Treatment
timeFrame: 12 months
measure: Change From Baseline In eGFR At Week 28
timeFrame: Baseline, Week 28
measure: Participants With Significant Improvement In eGFR Relative To Baseline At Week 28
timeFrame: Baseline, Week 28
measure: Participants With Significant Improvement In eGFR Relative To Baseline At Week 52
timeFrame: Baseline, Week 52
Other outcomes:
Locations:
city: Aurora
country: United States
facility: Clinical Study Site
state: Colorado
city: Lawrenceville
country: United States
facility: Clinical Study Site
state: Georgia
city: Iowa City
country: United States
facility: Clinical Study Site
state: Iowa
city: Baltimore
country: United States
facility: Clinical Study Site
state: Maryland
city: New York
country: United States
facility: Clinical Study Site
state: New York
city: New York
country: United States
facility: Clinical Study Site
state: New York
city: London
country: United Kingdom
facility: Clinical Study Site
Study officials:
References: